A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Tranexamic acid (Primary)
- Indications Gastrointestinal disorders; Post-surgical adhesions; Postoperative ileus
- Focus Proof of concept; Therapeutic Use
- Acronyms PROFILE
- Sponsors Leading BioSciences; Palisade Bio
- 17 Jun 2024 Status changed from active, no longer recruiting to completed.
- 09 Aug 2023 According to a Palisade Bio media release, primary endpoint (Change from baseline in extent and severity of intra-abdominal adhesions among subjects treated with LB1148 or placebo) has not been met.
- 09 Aug 2023 Topline results presented in Palisade Bio media release.